The past and future of neuroprotection in cerebral ischaemic stroke.

نویسندگان

Ashfaq Shuaib

Muhammad S Hussain

چکیده

Following the realization that cerebral tissue may survive for hours after an ischaemic insult, several agents with neuroprotective properties in small-animal models of cerebral ischaemia have been tested in patients with acute ischaemic stroke (AIS). Initial attempts at translating the positive effects of these agents from animal models to patients were unsuccessful, possibly as a result of poorly planned experiments in models of ischaemia, and/or clinical trials of AIS that were not optimized to show a positive effect. Newer neuroprotective agents that are believed to act later in the ischaemic cascade may offer a greater chance of success. However, before these agents can be introduced into clinical practice they must undergo assessment in rodent and large-animal models of AIS and, in particular, the dose-response relationship and the treatment time window should be defined. This should be followed by evaluation in carefully designed clinical trials of adequate power, involving subjects receiving an appropriate dose within an optimum time window following the onset of symptoms. There is hope that such careful strategies may guide continued progress in neuroprotective drug development.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

P39: The Neuroprotection Effect of Erythropoietin in Cerebral Ischemia

Cerebral ischemia causes death of millions people all over the world, annually and also suffering more people from neurological deficits and neuromuscular disorders. In our country, 250 to 300 people experience mild to severe stroke, daily. In this study we reviewed 120 original paper selected from PubMED database. Our keywords were erythropoietin, anti-inflammatory, stroke, neuropathy and cere...

متن کامل

Vitamin E Derivative Alpha-Tocotrienol Failed to Show Neuroprotective Effects after Embolic Stroke in Rats

Objective(s) Previous studies have demonstrated that pretreatment with alpha-tocotrienol (a-TCT) can reduce ischemic damage in mice following middle cerebral artery (MCA) occlusion. It is also reported to decrease stroke- dependent brain tissue damage in 12-Lox-deficient mice and spontaneously hypertensive rats. In the present study, the neuroprotective effects of a-TCT and rosiglitazone (RGZ)...

متن کامل

Neuroprotection and neurosupplementation in ischaemic brain.

Possible strategies for treating ischaemic stroke include: (i) neuroprotection (preventing damaged neurons from undergoing apoptosis in the acute phase of cerebral ischaemia), and (ii) neurosupplementation (the repair of broken neuronal networks with newly born neurons in the chronic phase of cerebral ischaemia). In this paper, we review our recent progress in development of these distinct new ...

متن کامل

Optimising Clinical Trial Design for Proof of Neuroprotection in Acute Ischaemic Stroke: The SAINT Clinical Trial Programme

The development of effective therapies for acute ischaemic stroke has proven to be a challenging task. The only approved therapy for acute ischaemic stroke remains intravenous recombinant tissue plasminogen activator initiated within 3 h of stroke onset, following a CT scan to exclude intracerebral haemorrhage. Many other therapies have been evaluated in Phase III clinical trials, including mor...

متن کامل